Ditropan XL couples a proven therapeutic with a leading drug delivery technology to help reduce the discomfort and embarrassment often associated with symptoms of overactive bladder. Although overactive bladder is most prevalent among women and older adults, the condition can affect people of all ages. These symptoms can interfere with some of the most basic daily activities, such as exercising, travelling and sleeping and may restrict social interactions with families and friends. In fact, many people with overactive bladder become socially isolated or even housebound because they fear the embarrassment of having wetting accidents in public. Ditropan XL is an effective and generally well-tolerated therapy that can help many patients experience a significant reduction in symptoms.
Overactive bladder remains widely underdiagnosed and undertreated.
In fact, an estimated 90 percent of patients with overactive bladder do not discuss the symptoms with their physician, primarily due to embarrassment, lack of self confidence and the common belief that overactive bladder is a normal part of aging. Many leading urologic and patient advocacy organisations have become increasingly vocal about the need for patients and healthcare professionals to better understand overactive bladder and its treatment. The efficacy and safety of Ditropan XL were demonstrated in 429 adult incontinent patients in three controlled studies and one open-label study. In these controlled studies, Ditropan XL demonstrated efficacy superior to placebo in the reduction of urge incontinence episodes, or wetting accidents. Patients treated with Ditropan XL experienced between 15 to 18 fewer urge incontinence episodes per week.